Merck (MRK) Change in Acquisitions & Divestments (2009 - 2025)
Merck (MRK) reported Change in Acquisitions & Divestments of $46.0 million for Q4 2025, up 112.43% year-over-year from $21.7 million in Q4 2024, and down 92.0% quarter-over-quarter from $575.0 million in Q3 2025.
Merck (MRK) Change in Acquisitions & Divestments (2009 - 2025) Analysis & Trends
Merck (MRK) has 17 years of Change in Acquisitions & Divestments data on file, last reported at $46.0 million in Q4 2025.
- Change in Acquisitions & Divestments for Q4 2025 came in at $46.0 million, up 112.43% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.2 billion (up 523.47% YoY), and the FY2025 annual result was $1.7 billion, changed N/A from the prior year.
- Change in Acquisitions & Divestments fell to $46.0 million in Q4 2025 per MRK's latest filing, from $575.0 million in the prior quarter.
- Over five years, Change in Acquisitions & Divestments peaked at $704.0 million in Q3 2023 and troughed at -$370.0 million in Q4 2024.
- A 5-year average of $267.5 million and a median of $285.0 million in 2023 frame the typical range for Change in Acquisitions & Divestments.
- The sharpest annual moves came in 2023 and 2024: Change in Acquisitions & Divestments jumped 49900.0% in 2023, then sank 318.93% in 2024.
- A 5-year view of Change in Acquisitions & Divestments shows it stood at $529.0 million in 2021, then plunged by 97.73% to $12.0 million in 2022, then surged by 1308.33% to $169.0 million in 2023, then slumped by 318.93% to -$370.0 million in 2024, then surged by 112.43% to $46.0 million in 2025.
- Business Quant data shows MRK's Change in Acquisitions & Divestments at $46.0 million in Q4 2025, $575.0 million in Q3 2025, and $601.0 million in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn |
| 10 | Novartis Ag | 108.28 Bn | 107.60 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 46.00 Mn |
| Dec 31, 2025 | 46.00 Mn |
| Sep 30, 2025 | 575.00 Mn |
| Sep 30, 2025 | 575.00 Mn |
| Jun 30, 2025 | 601.00 Mn |
| Jun 30, 2025 | 601.00 Mn |
| Mar 31, 2025 | 456.00 Mn |
| Mar 31, 2025 | 456.00 Mn |
| Dec 31, 2024 | -370.00 Mn |
| Dec 31, 2024 | -370.00 Mn |
| Sep 30, 2024 | 50.00 Mn |
| Sep 30, 2024 | 50.00 Mn |
| Jun 30, 2024 | 60.00 Mn |
| Jun 30, 2024 | 60.00 Mn |
| Mar 31, 2024 | 260.00 Mn |
| Mar 31, 2024 | 260.00 Mn |
| Dec 31, 2023 | 169.00 Mn |
| Dec 31, 2023 | 169.00 Mn |
| Sep 30, 2023 | 704.00 Mn |
| Sep 30, 2023 | 704.00 Mn |